2024
De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy
Yarbrough W, Schrank T, Burtness B, Issaeva N. De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy. Viruses 2024, 16: 536. PMID: 38675879, PMCID: PMC11053602, DOI: 10.3390/v16040536.Peer-Reviewed Original ResearchConceptsHPV+ HNSCCHPV-associated head and neck cancerHead and neck cancerHuman papillomavirus-associatedDe-escalation therapyDetect recurrent diseaseTreatment of recurrenceHPV-associated cancersHead and neckEarly treatment of recurrencePapillomavirus-associatedDevelopment of biomarkersResponsive tumorsRecurrent diseaseStandard therapyCompanion biomarkersHPV carcinogenesisHPV vaccinationNeck cancerPoor prognosisDecrease morbidityHNSCCEarly treatmentMolecular vulnerabilitiesPersonalized therapy
2023
Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors
Schrank T, Kothari A, Weir W, Stepp W, Rehmani H, Liu X, Wang X, Sewell A, Li X, Tasoulas J, Kim S, Yarbrough G, Xie Y, Flamand Y, Marur S, Hayward M, Wu D, Burtness B, Anderson K, Baldwin A, Yarbrough W, Issaeva N. Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2216532120. PMID: 37523561, PMCID: PMC10410762, DOI: 10.1073/pnas.2216532120.Peer-Reviewed Original ResearchConceptsNF-κB-related genesEstrogen receptor alpha expressionDeintensification of therapyTreatment-related morbidityTumor-infiltrating CD4Receptor alpha expressionHPV carcinogenesisRadiosensitization of headOncogenic subtypesPIK3CA alterationsHNSCC tumorsPatient outcomesNeck tumorsT cellsTreatment responseHNSCC cellsTherapeutic intensityAtypical featuresIndependent cohortAlpha expressionNF-κBActive tumorTNF receptorTumorsPatient data
2021
Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?
Cmelak AJ, Ferris RL, Chen AM, Seiwert T, Burtness B. Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable? Journal Of Clinical Oncology 2021, 39: 2732-2733. PMID: 34043410, DOI: 10.1200/jco.21.00594.Peer-Reviewed Original ResearchHypoxia-Guided Therapy for Human Papillomavirus-Associated Oropharynx Cancer
Burtness B, Contessa J. Hypoxia-Guided Therapy for Human Papillomavirus-Associated Oropharynx Cancer. Journal Of The National Cancer Institute 2021, 113: 652-653. PMID: 33429429, PMCID: PMC8168139, DOI: 10.1093/jnci/djaa187.Peer-Reviewed Original Research
2020
PET/CT radiomics signature of human papilloma virus association in oropharyngeal squamous cell carcinoma
Haider SP, Mahajan A, Zeevi T, Baumeister P, Reichel C, Sharaf K, Forghani R, Kucukkaya AS, Kann BH, Judson BL, Prasad ML, Burtness B, Payabvash S. PET/CT radiomics signature of human papilloma virus association in oropharyngeal squamous cell carcinoma. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 2978-2991. PMID: 32399621, DOI: 10.1007/s00259-020-04839-2.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaMetastatic cervical lymph nodesCervical lymph nodesLymph nodesSquamous cell carcinomaPrimary tumorPET/CTHPV associationCell carcinomaRadiomics signatureVolume of interestHuman papilloma virus associationHuman papillomavirus associationMulti-national cohortNon-contrast CTHPV statusFDG-PETExternal cohortVirus associationFinal modelTumorsRadiomic featuresCTSignificant differencesLesion features
2019
Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?
Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? American Society Of Clinical Oncology Educational Book 2019, 39: 364-372. PMID: 31099643, DOI: 10.1200/edbk_238315.Peer-Reviewed Original ResearchConceptsDe-escalate treatmentOropharyngeal carcinomaHPV-positive oropharyngeal carcinomaNeck cancer clinical researchNew systemic agentsPhase II trialPhase III trialsTreatment-related morbidityHigh cure ratesCancer clinical researchConcurrent cisplatinII trialOropharynx cancerPrimary surgeryDose intensityIII trialsInstitutional seriesInvasive resectionMultimodality treatmentSystemic agentsSystemic therapyPrimary diseaseCure rateToxic therapiesMultimodality strategy
2017
Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer. Clinical Cancer Research 2017, 23: 7276-7287. PMID: 28916527, DOI: 10.1158/1078-0432.ccr-17-1438.Peer-Reviewed Original ResearchConceptsClinical trialsHNSCC cellsMatrix metalloproteinasesHuman papillomavirus-associated headNeck squamous cell carcinomaSquamous cell carcinomaAbility of HPVClin Cancer ResTumor cell proliferationNeck cancer cellsWindow trialsCell carcinomaEffective therapyPreclinical modelsHPVHPV oncogenesMouse modelMouse blood vesselsDNA demethylating agentHNSCCXenografted tumorsHPV genesIFN responseTherapyTumor samplesComparison of Survival Outcomes Among Human Papillomavirus–Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study
Kelly JR, Park HS, An Y, Contessa JN, Yarbrough WG, Burtness BA, Decker R, Husain Z. Comparison of Survival Outcomes Among Human Papillomavirus–Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study. JAMA Oncology 2017, 3: 1107-1111. PMID: 28056116, PMCID: PMC5824218, DOI: 10.1001/jamaoncol.2016.5769.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaHPV-negative oropharyngeal squamous cell carcinomaNegative oropharyngeal squamous cell carcinomaMultivariable Cox regressionPrimary surgical resectionOverall survivalUpfront surgerySurgical resectionObservational studyChemoradiation therapySurgical patientsAdjuvant CRTSurvival outcomesCox regressionNational Cancer Data BaseOropharyngeal squamous cell cancerDefinitive chemoradiation therapyMost surgical patientsConcurrent chemoradiation therapyHPV-positive diseaseMargin-negative resectionOptimal patient selectionPrimary treatment modalityUpfront surgical resectionKaplan-Meier analysisPurpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials
Marur S, Cmelak AJ, Burtness B. Purpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials. Journal Of Clinical Oncology 2017, 35: jco.2017.72.291. PMID: 28430529, DOI: 10.1200/jco.2017.72.2918.Peer-Reviewed Original ResearchThe prognostic value of extranodal extension in human papillomavirus‐associated oropharyngeal squamous cell carcinoma
An Y, Park HS, Kelly JR, Stahl JM, Yarbrough WG, Burtness BA, Contessa JN, Decker RH, Koshy M, Husain ZA. The prognostic value of extranodal extension in human papillomavirus‐associated oropharyngeal squamous cell carcinoma. Cancer 2017, 123: 2762-2772. PMID: 28323338, DOI: 10.1002/cncr.30598.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellChemoradiotherapy, AdjuvantFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingOropharyngeal NeoplasmsOtorhinolaryngologic Surgical ProceduresPapillomaviridaePapillomavirus InfectionsPrognosisPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSquamous Cell Carcinoma of Head and NeckSurvival RateConceptsOropharyngeal squamous cell carcinomaENE-positive patientsHPV-positive oropharyngeal squamous cell carcinomaExtranodal extensionHPV-positive patientsOverall survivalPrimary surgeryPT4 tumorsAdjuvant chemoradiationConcurrent chemoradiotherapyAdjuvant treatmentPositive oropharyngeal squamous cell carcinomaPT3/pT4 tumorsMultivariable Cox regression analysisNational Cancer Data BasePredictors of OSPropensity score-matched comparisonAdjuvant concurrent chemoradiotherapyCharlson-Deyo scoreInvolved lymph nodesAdverse prognostic factorInferior overall survivalLymph node statusCox regression analysisSingle-institution studyTRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma
Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma. Cancer 2017, 123: 1778-1790. PMID: 28295222, PMCID: PMC5419871, DOI: 10.1002/cncr.30570.Peer-Reviewed Original ResearchConceptsHPV-positive HNSCCNeck squamous cell carcinomaDe-escalation therapyHPV-positive HNSCCsMechanisms of HPVRecurrent metastatic diseaseBetter overall survivalSquamous cell carcinomaNuclear factor-κB signalingFactor-κB signalingNew therapeutic strategiesNuclear factor κBHPV vaccineCancer Genome AtlasCurative optionHPV statusMetastatic diseaseOverall survivalCervical cancerPatient survivalSmoking characteristicsCell carcinomaHuman papillomavirusLifelong morbidityClinical trialsThe risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation
Lee NCJ, Kelly JR, Park HS, Yarbrough WG, Burtness BA, Husain ZA. The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation. Practical Radiation Oncology 2017, 7: e317-e321. PMID: 28356201, DOI: 10.1016/j.prro.2017.02.004.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellFemaleHead and Neck NeoplasmsHumansLymph Node ExcisionLymph NodesLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrgan Sparing TreatmentsOropharyngeal NeoplasmsPapillomaviridaeParotid GlandRadiotherapy, AdjuvantRetrospective StudiesSquamous Cell Carcinoma of Head and NeckSubmandibular GlandXerostomiaConceptsOropharyngeal squamous cell cancerPositive nodesNodal involvementLevel Ib lymph nodesIb lymph nodesPrimary surgical treatmentRetrospective chart reviewCohort of patientsCommon side effectsSquamous cell cancerIpsilateral neckNodal dissectionOropharynx cancerChart reviewNeck irradiationLymph nodesSurgical treatmentCell cancerLevel IbNodal stationsNegative imagingRadiation therapyLower riskSide effectsPatients
2016
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Molecular Cancer Therapeutics 2016, 15: 2486-2497. PMID: 27507850, PMCID: PMC5522587, DOI: 10.1158/1535-7163.mct-16-0243.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ErbB ReceptorsFemaleHead and Neck NeoplasmsHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedModels, BiologicalNeoplasm StagingPapillomaviridaePapillomavirus InfectionsPhosphorylationPrognosisProtein Kinase InhibitorsReceptor, ErbB-2Retinoblastoma Binding ProteinsUbiquitin-Protein LigasesConceptsEpidermal growth factor receptorRetinoblastoma 1Neck squamous cell carcinomaExpression of EGFRSquamous cell carcinomaCDK4/6 inhibitor palbociclibSignificant survival differenceResponse predictive biomarkersHPV-negative HNSCCHigh epidermal growth factor receptorStratification of casesImportant therapeutic targetSynergistic inhibitory effectGrowth factor receptorCell cycle modulatorsCell carcinomaDisease stageInhibitor palbociclibHuman papillomavirusSurvival differencesHNSCC samplesTherapeutic decisionsHNSCC cellsAnatomic locationDrug combinations
2013
Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer
Fang CY, Egleston BL, Ridge JA, Lango MN, Bovbjerg DH, Studts JL, Burtness BA, Einarson MB, Klein–Szanto A. Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer. Head & Neck 2013, 36: 1113-1119. PMID: 23804308, PMCID: PMC4099415, DOI: 10.1002/hed.23421.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorEndothelial growth factorPsychosocial functioningVEGF expressionNeck squamous cell carcinomaGrowth factorSquamous cell carcinomaTumor VEGF expressionGreater VEGF expressionHPV statusPoor outcomeCell carcinomaPatient populationPoor prognosisDisease stageHuman papillomavirusNeck cancerBiobehavioral pathwaysPatientsHPVTumor samplesVEGF analysisHNSCCsPrognosisSurgeryNovel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. The Lancet Oncology 2013, 14: e302-e309. PMID: 23816296, DOI: 10.1016/s1470-2045(13)70085-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabDrug DesignDrug Resistance, NeoplasmErbB ReceptorsHead and Neck NeoplasmsHistone Deacetylase InhibitorsHumansMolecular Targeted TherapyPapillomaviridaeProtein Kinase InhibitorsProto-Oncogene Proteins c-metReceptor, ErbB-2Signal TransductionTreatment OutcomeConceptsHPV-negative headNeck cancerHuman papillomavirusEGFR inhibitionSingle-agent cetuximabLow cure rateMonoclonal antibody cetuximabActive therapyCytotoxic chemotherapyDisease survivalCure rateMechanisms of resistanceAntibody cetuximabResponse rateCetuximabEGFRNovel targetReceptor tyrosine kinasesCancerTherapyHistone deacetylaseChemotherapyHabitual exposureModest effectNuclear functions